AcuraBio expands cGMP plasmid DNA CDMO services with Cytiva's latest single-use purification technology to alleviate supply constraints for mRNA and cell & gene therapies
AcuraBio selects Cytiva's latest two-step purification protocol to offer a productive plasmid DNA service to its customers globally to alleviate supply constraints for mRNA and cell & gene therapies The latest purification technology will offer efficient processing time for plasmid DNA production BRISBANE, Australia, Feb. 10, 2023 /PRNewswire/ -- AcuraBio, a leading Australian biopharmaceutical contract development and manufacturing organization (CDMO), will provide a cGMP plasmid DNA CDMO service to the world using Cytiva's new process platform technology. Jon Ince (left), Genera...